Immunotoxin therapy of cancer.
Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
Pastan
Ira
I
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892-4264, USA. pastani@mail.nih.gov
Hassan
Raffit
R
Fitzgerald
David J
DJ
Kreitman
Robert J
RJ
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001427:Bacterial Toxins / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy; D000922:Immunotoxins / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001427:Bacterial Toxins; D007135:Immunoglobulin Variable Region; D000922:Immunotoxins; D011994:Recombinant Proteins